Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
Holding ALMS?
Track your performance easily
ALMS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$10.37 - $13.53
Previous Close$11.34
Volume26.92K
Average Volume (3M)172.63K
Market Cap
$526.01M
Enterprise Value$433.81M
Total Cash (Recent Filing)$133.73M
Total Debt (Recent Filing)$32.08M
Price to Earnings (P/E)―
Beta-0.31
Next Earnings
Aug 13, 2024EPS Estimate
-$1.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,403,302
10 Day Avg. Volume128,586
30 Day Avg. Volume172,632
Standard Deviation0.08
R-Squared1.00
Alpha-0.18
Financial Highlights & Ratios
Price to Book (P/B)-1.60
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.84
Forecast
1Y Price Target
$27.50Price Target Upside146.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $10.37 and its highest was $13.53 in the past 12 months.
What is Alumis Inc.’s market cap?
Currently, no data Available
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Aug 13, 2024 which is 37 days ago.
How were Alumis Inc.’s earnings last quarter?
Currently, no data Available
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -$1.46.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 47,218,395 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
---
Alumis Inc. Stock Smart Score
Company Description
Alumis Inc.
Alumis' mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis, and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis, for which we expect to report results in 2026 and by the end of 2024, respectively.
---
ALMS Stock 12 Month Forecast
Average Price Target
$27.50
▲(146.86% Upside)
Technical Analysis
Best Analysts Covering ALMS
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-10.35%
reiterated a buy rating last month
Copying Thomas Smith's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.35% per trade.
---